Brepocitinib Overview & RVT-3101 Update

Brepocitinib Overview First-in-class dual TYK2/JAK1 inhibitor being developed for specialty autoimmune diseases with high morbidity/mortality and limited treatment options Unique, Dual-Targeting Mechanism Robust Clinical Data Distinctive Strategy Tailored to Novel Mechanism Dual inhibition of TYK2 and JAKI is expected to potentially provide greater efficacy than agents that inhibit either alone in multiple highly inflammatory autoimmune diseases Statistically significant and clinically meaningful benefit in all five placebo-controlled studies completed to date (oral, once-daily) Exposure in >1,000 subjects and patients to date; safety profile consistent with approved JAK inhibitors Rather than standard set of highly competitive broad market JAK indications, pursue series of uncrowded, orphan and specialty autoimmune diseases with highest morbidity/mortality and where we expect that both TYK2 and JAK1 inhibition will contribute to efficacy Two Ongoing Registrational Programs Single registrational phase 3 study in dermatomyositis initiated Large, global phase 2B study in lupus with enrollment complete; data anticipated in 2H 2023 (designed to serve as one of two registrational studies) Additional indications to be announced Strong Intellectual Property Position Patent protection expected through ~2039 roivant 25 25 For investor audiences only

View entire presentation